Sanofi poaches exec from Novartis

Sanofi has selected Paul Hudson, Novartis' pharma chief, to serve as its new CEO, according to Bloomberg.

Mr. Hudson will replace Oliver Brandicourt, who will retire in September at the age of 63. Mr. Brandicourt has served as CEO of the drugmaker since 2015.

Mr. Hudson has led Novartis' pharma unit since 2016 and is credited with launching key medicines for the drugmaker. Before coming to Novartis, Mr. Hudson served as the U.S. pharma chief for AstraZeneca.

Marie-France Tschudin will become the new leader of the Novartis pharmaceuticals business unit.

More articles on pharmacy:
Viewpoint: The $2.1M drug price record won't last long
Purdue Pharma hit with 4 more opioid lawsuits: 4 things to know
EpiPen shortage will drag on: 4 things to know

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Featured Content

Featured Webinars

Featured Whitepapers